CCA
PACB icon

Clearwater Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Clearwater Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,482
Closed -$43.1K – 162
2024
Q1 		$43.1K Sell
11,482
-402
-3% -$2.35K ﹤0.01% 157
2023
Q4 		$117K Hold
11,884
– – 0.01% 152
2023
Q3 		$99.2K Sell
11,884
-620
-5% -$7.09K 0.01% 138
2023
Q2 		$166K Hold
12,504
– – 0.02% 142
2023
Q1 		$145K Hold
12,504
– – 0.02% 147
2022
Q4 		$102K Sell
12,504
-1,600
-11% -$13.8K 0.01% 154
2022
Q3 		$82K Hold
14,104
– – 0.01% 150
2022
Q2 		$62K Buy
14,104
+800
+6% +$4.86K 0.01% 146
2022
Q1 		$121K Buy
13,304
+2,910
+28% +$33.5K 0.01% 163
2021
Q4 		$213K Buy
10,394
+1,365
+15% +$32.9K 0.02% 159
2021
Q3 		$231K Buy
9,029
+1,237
+16% +$36.6K 0.03% 156
2021
Q2 		$272K Buy
7,792
+398
+5% +$11.6K 0.03% 145
2021
Q1 		$246K Buy
+7,394
New +$259K 0.03% 148

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearwater Capital Advisors's PACB Position: Q2 2024 in Review

Clearwater Capital Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 11,482 shares — an estimated $43.1K sold.

Clearwater Capital Advisors first reported a position in PACB in Q1 2021 and held it in 13 quarters. The position peaked at $272K in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Clearwater Capital Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Clearwater Capital Advisors sold 11,482 Pacific Biosciences shares in Q2 2024, an estimated $43.1K.
  • Clearwater Capital Advisors first reported a position in Pacific Biosciences in Q1 2021 and held it in 13 quarters.
  • Clearwater Capital Advisors's Pacific Biosciences position peaked at $272K in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Clearwater Capital Advisors's 13F filing for Q2 2024, filed 6 Aug 2024.